Literature DB >> 8147935

Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus.

M T Herranz1, G Rivier, M A Khamashta, K U Blaser, G R Hughes.   

Abstract

OBJECTIVE: To determine whether the occurrence of seizures is correlated with the presence of serum antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE) patients.
METHODS: The study included 221 unselected patients with SLE. Of these, 21 patients with epileptic seizures not attributed to any cause other than SLE were identified. Epilepsy was diagnosed by clinical history and electroencephalography. Blood samples were tested for the presence of antibodies to cardiolipin (aCL, IgG and IgM isotypes) and lupus anticoagulant (LAC).
RESULTS: LAC was detected in 43.8% of the patients with epilepsy and in 20.8% of controls (P = 0.057). A statistically significant association was found between moderate-to-high titers of IgG aCL and the presence of seizures (P = 0.02). Brain computed tomography and/or magnetic resonance imaging scanning was performed in 14 patients. All patients with abnormal features found on these tests had positive aPL (P = 0.03). Nine patients (42.9%) had at least 1 of the classic features associated with the aPL syndrome.
CONCLUSION: We confirmed that epilepsy as a primary neuropsychiatric event is significantly associated with moderate-to-high titers of IgG aCL in SLE patients. Our results suggest that aPL could have a role in the etiopathogenesis of epilepsy in SLE.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147935     DOI: 10.1002/art.1780370418

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

Review 1.  Cognitive impairment in antiphospholipid syndrome: evidence from animal models.

Authors:  Simone Appenzeller; Aline Tamires Lapa; Caio Rodrigues Guirau; Jozélio Freire de Carvalho; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2012-01-05       Impact factor: 2.980

Review 2.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  D Tanne; S Hassin-Baer
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

3.  Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

Authors:  L Ziporen; Y Shoenfeld; Y Levy; A D Korczyn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

4.  Retinal disease in patients with systemic lupus erythematosus.

Authors:  O Ushiyama; K Ushiyama; S Koarada; Y Tada; N Suzuki; A Ohta; S Oono; K Nagasawa
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

5.  Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype.

Authors:  G Lakos; E Kiss; N Regëczy; P Tarján; P Soltész; M Zeher; E Bodolay; S Szakony; S Sipka; G Szegedi
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

6.  Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus.

Authors:  Shuzo Sato; Makiko Yashiro; Tomoyuki Asano; Hiroko Kobayashi; Hiroshi Watanabe; Kiyoshi Migita
Journal:  Clin Rheumatol       Date:  2017-04-28       Impact factor: 2.980

7.  [A cerebral watershed infarction after general anaesthesia in a patient with increased anti-cardiolipin antibody level].

Authors:  S J C Verbrugge; M Klimek; J Klein
Journal:  Anaesthesist       Date:  2004-04       Impact factor: 1.041

Review 8.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

9.  Neuropsychiatric lupus.

Authors:  Amal Alkhotani
Journal:  Sultan Qaboos Univ Med J       Date:  2013-02-27

10.  Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India.

Authors:  Surjit Singh; Mukesh Kumar Gupta; Jasmina Ahluwalia; Paramjeet Singh; Prahbhjot Malhi
Journal:  Rheumatol Int       Date:  2009-03-22       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.